Ligand Pharmaceuticals Stock (NASDAQ:LGND)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$248.24

52W Range

$110.00 - $258.57

50D Avg

$225.01

200D Avg

$198.91

Market Cap

$5.10B

Avg Vol (3M)

$221.71K

Beta

1.04

Div Yield

-

LGND Company Profile


Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

68

IPO Date

Nov 18, 1992

Website

LGND Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Royalty, Evomela$5.94M$8.68M$10.20M
Royalty, Kyprolis$35.53M$38.38M$30.12M
Royalty, Other$10.37M$8.95M$7.63M
Service$6.81M$25.53M$1.12M
Contract Revenue$66.87M$27.48M$19.22M
Financial Royalty Assets$28.47M$13.44M-
Intangible Royalty Assets$132.53M$95.33M-
License Fees$6.99M$1.94M$2.85M
Material Sales, Captisol, Core$40.21M$30.88M$16.43M
Royalty$161.00M$108.77M$72.53M
Material Sales, Captisol-$30.88M$104.50M
Milestone--$9.15M
Material Sales, Captisol, COVID--$88.07M
License Fees, Milestones, and Other Product, Other--$6.11M

Fiscal year ends in Dec 25 | Currency in USD

LGND Financial Summary


Dec 25Dec 24Dec 23
Revenue$268.09M$167.13M$131.31M
Operating Income$47.20M$-22.61M$11.94M
Net Income$124.45M$-4.03M$52.15M
EBITDA$158.96M$40.79M$100.84M
Basic EPS$6.44$-0.22$3.02
Diluted EPS$6.13$-0.22$2.94

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 09, 26 | 12:00 AM
Q4 25Feb 26, 26 | 12:00 AM
Q3 25Nov 08, 25 | 8:30 AM

Peer Comparison


TickerCompany
ADMAADMA Biologics, Inc.
VKTXViking Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals, Inc.
BLTEBelite Bio, Inc
PRAXPraxis Precision Medicines, Inc.
ACADACADIA Pharmaceuticals Inc.
SLNOSoleno Therapeutics, Inc.
NAMSNewAmsterdam Pharma Company N.V.
DYNDyne Therapeutics, Inc.